|
Best-in-class BCL-XL PROTAC
|
Ophthalmology disease
|
Ocular fundus pathology,DME,DR
|
PCC
|
Global
| |
|
GPCR selective agonist
|
Immunological disease
|
Duchenne muscular dystrophy,Systemic lupus erythematous;,Ulcerative colitis;,Ankylosing spondylitis
|
PCC
|
Global
| |
|
See in our "Antibody Licensing" platform
|
|
Next to "Licensing" Tab in the top
|
PCC
|
| |
|
Selective POLQ inhibitor
|
Oncology/Cancer
|
Pancreatic cancer,BRCAm ,other DDR-deficient tumors
|
PCC
|
Global
| |
|
Best-in-class IRAK4 Degrader
|
Immunological disease
|
Psoriasis,RA,Inflammatory bowel disease (IBD),or other autoimmune inflammatory diseases
|
Preclinical
|
Global
| |
|
CCR8 mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
|
FRa BsAb (sequence cooperation)
|
Oncology/Cancer
|
Ovarian cancer
|
Preclinical
|
Global
| |
|
GCC mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
|
Novel target small molecule inhibitor
|
Cardiovascular
|
Myocardial ischemia-reperfusion injury,Heart failure prevention;
|
Preclinical
|
Global
| |
|
Novel transport-Targeting Small molecular - Paclitaxel conjugate
|
Oncology/Cancer
|
Lung squamous cell carcinoma (LSCC),Head-neck cancer,Pancreatic cancer
|
Preclinical
|
Global
| |
|
First-in-class GPCR inhibitor targeting BxR eye drops for retinal diseases
|
Ophthalmology disease
|
Diabetic retinopathy,Macular degeneration,Inflammatory ocular disease,Postoperative care for eye surgery
|
IND
|
Global
| |
|
CD47 mAb
|
Oncology/Cancer
|
Advanced solid tumor,Advanced hematological tumor
|
IND
|
Global
| |
|
CLDN 18.2 CAR-T
|
Oncology/Cancer
|
Gastric Cancer,Pancreatic Cancer
|
IND
|
Global
| |
|
EGFR/cMet ADC
|
Oncology/Cancer
|
Gastric cancer,Pancreatic cancer,Colorectal cancer, Lung cancer
|
IND
|
Global
| |
|
Novel oligosaccharide
|
Renal diseases
|
Acute Kidney Injury (before heart surgery and after AKI)
|
IND
|
Global
| |
